{"id":"glisentide","rwe":[{"pmid":"39546470","year":"2024","title":"Repurposing of drug candidates against Epstein-Barr virus: Virtual screening, docking computations, molecular dynamics, and quantum mechanical study.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"38931460","year":"2024","title":"Approved and Commercialized Antidiabetic Medicines (Excluding Insulin) in Seven European Countries-A Cross-Sectional Comparison.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"12191707","year":"2002","title":"Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide.","finding":"","journal":"Journal of pharmaceutical and biomedical analysis","studyType":"Clinical Study"},{"pmid":"10486438","year":"1999","title":"Evidence for polymorphism in glisentide.","finding":"","journal":"International journal of pharmaceutics","studyType":"Clinical Study"},{"pmid":"1361542","year":"1992","title":"In-vitro protein binding interaction between a metabolite of triflusal, 2-hydroxy-4-trifluoromethylbenzoic acid and other drugs.","finding":"","journal":"The Journal of pharmacy and pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"glisentide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"staticum","offLabel":[],"synonyms":["glipentida","glypentide","glisentide","glipentide","staticum"],"timeline":[],"approvals":[],"brandName":"Staticum","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"glisentide","explanation":"Imagine your body's cells have locks on them, and glisentide has a key that fits into one of those locks. When the key fits, it can turn the lock and change how the cell works. This can help to treat certain health conditions, but the details of how it works are still being studied.","oneSentence":"Glisentide works by binding to a specific target, but the exact nature of this interaction is not well understood.","technicalDetail":"Glisentide is a small molecule that interacts with a specific protein target, but the exact nature of this interaction is not well understood and requires further research."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1303","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GLISENTIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:45:38.326477","biosimilars":[],"competitors":[],"genericName":"glisentide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"392TQL1E2Z","CHEBI":"CHEBI:135725","INN_ID":"3163","UMLSCUI":"C0061763","ChEMBL_ID":"CHEMBL2105089","KEGG_DRUG":"D02428","PUBCHEM_CID":"65779","MESH_SUPPLEMENTAL_RECORD_UI":"C401283"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":5,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2024","pmid":"39546470","title":"Repurposing of drug candidates against Epstein-Barr virus: Virtual screening, docking computations, molecular dynamics, and quantum mechanical study.","journal":"PloS one"},{"date":"2024 Jun 17","pmid":"38931460","title":"Approved and Commercialized Antidiabetic Medicines (Excluding Insulin) in Seven European Countries-A Cross-Sectional Comparison.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2002 Sep 5","pmid":"12191707","title":"Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide.","journal":"Journal of pharmaceutical and biomedical analysis"},{"date":"1999 Sep 20","pmid":"10486438","title":"Evidence for polymorphism in glisentide.","journal":"International journal of pharmaceutics"},{"date":"1992 Nov","pmid":"1361542","title":"In-vitro protein binding interaction between a metabolite of triflusal, 2-hydroxy-4-trifluoromethylbenzoic acid and other drugs.","journal":"The Journal of pharmacy and pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Staticum (Glisentide) is a small molecule drug in the glisentide class, but its target and exact mechanism of action are unknown. It is not clear if it has been approved by the FDA or if it is patented or off-patent. The approved indications for Staticum are also unknown. As a result, there is limited information available about its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand this medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}